Phase 4 N=60 SISTERS: Spasticity In Stroke Study - Randomized Study
Severe Spasticity
Primary: Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 — -0.99; -0.43 units on a scale — p=0.0140
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=55 Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
Major Depressive Disorder · Generalized Anxiety Disorder
Primary: MADRS — 27.1; 28.6; 9.1; 15.7 units on a scale
Phase 2 N=19 Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: The Number of Participants With In Vitro Dasatinib Sensitivity in Predicting Clinical Activity — 5; 4; 4; 0 Participants — p=0.0106
Phase 2 N=36 Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
Refractory Chronic Cough
Primary: Cough Reflex Sensitivity to Capsaicin in Participants Who Received Gefapixant 100 mg and Placebo (Period 1 & Period 2 Combined) — 3.05; 3.04; 1.72; 1.41 natural log (µM)…
Phase 2 N=201 Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
Primary Open-Angle Glaucoma (POAG) · Ocular Hypertension (OHT)
Primary: Mean Intraocular Pressure (IOP) — -6.4; -6.8; -6.4; -7.1 mm of mercury
Phase 3 N=184 Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
Chronic Troublesome Sialorrhea · Parkinson's Disease · Post-stroke
Primary: MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 4 — -0.04; -0.06; -0.13 gram per minute (g/min) — p== 0.004
Phase 2 N=51 Omega-3 Fatty Acids in Adolescent Depression
Adolescent Depression
Primary: Children's Depressive Rating Scale - Revised (CDRS-R) — 50.2; 49.5; 35.2; 36.5 units on a scale
Phase 4 N=349 DUAC® Early Onset Efficacy Study in Japanese Subjects
Acne Vulgaris
Primary: Percent Change in Total Lesion Counts (TLs) From Baseline to Week 2 — -42.16; -35.33 Percent change in lesions — p=0.008
N/A N=50 HeartMate 3™ CE Mark Clinical Investigation Plan
Advanced Refractory Left Ventricular Heart Failure
Primary: Survival — 92 Percentage of Participants who Survived
Phase 3 N=27,564 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Dyslipidemia
Primary: Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization — 3.11; 2.74; 6.01; 5.31 percentage of…
Phase 2 N=28 Circadian Rhythms of Aqueous Humor Dynamics in Humans
Glaucoma
Primary: Intraocular Pressure — 17.6; 16.4; 20.2; 17.0 mmHg — p=<.05
Phase 4 N=28 The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading
Attention Deficit/Hyperactivity Disorder
Primary: Gray Oral Reading Rest, Fourth Edition (GORT-4) — 8.27 units on a scale
Phase 2 N=20 Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
Exudative Age Related Macular Degeneration
Primary: Change in Central Subfield Thickness on OCT From Baseline to Week 36 — -54; -.1 microns
Phase 4 N=27 Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD
ADHD · Attention Deficit Hyperactivity Disorder
Primary: Go/No-go Task Performance Correct Inhibitions — 91; 89; 94; 92 percentage correct inhibitions
N/A N=20,031 Early Warning System for Clinical Deterioration on General Hospital Wards
Escalation of Care · Cardiopulmonary Arrest · Respiratory Arrest
Primary: Transfer to ICU or Unexpected Death Within 24 Hrs of Identification by the EWS Algorithm — 426; 444 participants